Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-03-27
Target enrollment:
Participant gender:
Summary
The prognosis of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or
modified-FOLFIRINOX as the first-line chemotherapeutic regimen. Studies have shown that
immunotherapy with Anti-PD-1 antibody can effectively increase the response rate and prolong
patient survival in a number of cancer diseases. Here investigators intend to compare the
therapeutic effects of modified-FOLFIRINOX alone and the combination of modified-FOLFIRINOX
and Anti-PD-1 antibody in patients with metastatic pancreatic cancer.